Search results for: 'Drug Discovery and Early Development Outsourcing Services'

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) encompasses insights across advances in targeted neurological therapies, cancer treatments, and AI-powered drug development. The TOE also features innovators for treatment of metabolic diseases such as obesity and heart failure.The Life Science, Health & Wellnes...

09 Sep 2024  |  Global  |  Technology Research

AI-based Drug Repurposing Market, Growth Opportunities, Global, 2024-2029

AI-based Drug Repurposing is emerging as a new and faster approach to bringing drugs to patients.

Infographics

×

This study analyzes the emergence of AI-based drug repurposing and examines the factors driving and hindering adoption. The limitation of traditional drug discovery has led to the growing interest in AI -based drug repurposing, which offers numerous advantages in terms of time, speed, and cost. AI-based drug repurposing has been explored across dif...

25 Apr 2022  |  North America  |  Frost Radar

Frost Radar™: Artificial Intelligence-enabled Drug Discovery, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

Pharmaceutical drug discovery and development has been suffering from declining success rates with new molecules primarily because of poor external validity of preclinical models and lack of efficacy of the molecule in terms of the intended disease indication. Drug success rates continue to be in the range of only 1 in 10 that enters clinical phase...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules, and the rate of return has shrunk from 16% in 2011 to almost 11% in 2018. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16Percentage in 2011 to almost 11Percentage in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniqu...

The application of Generative AI (Gen AI) in healthcare is a rapidly growing field. In recent years, emerging applications in drug discovery and development, medical imaging analysis, digital twins, synthetic data, and electronic health records management, and virtual assistants have garnered significant interest thanks to their potential to revolu...

28 Aug 2020  |  Global  |  Technology Research

Data Science Impacting the Pharmaceutical Industry

Part I: Drug Discovery Applications

Infographics

×

Data science and AI have the potential to transform drug discovery in terms of costs, speed and efficiency. With explosion in biomedical data, data sharing and analysis platforms have surged. AI technologies are moving to the next phase of advancements, and when combined with other emerging tech areas, AI is expected to witness a full fledged adopt...

Brands use outsourcing as a competitive strategy to get a multitude of benefits, including cost savings, best-in-class technology, business flexibility, access to skilled talent, and a blend of locations and delivery models. Customer experience (CX) outsourcing vendors partner with clients to understand their business challenges and offer solutions...

The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...